Retail Traders Ditch Tesla, Apple, Google For Pharma Stocks Like Ozempic-Maker Novo Nordisk And Eli Lilly: JPMorgan

Retail traders have been observed to be selling off their shares in the ‘Magnificent Seven’ tech stocks, with a noticeable shift towards pharmaceutical stocks, according to a recent report by JPMorgan.

What Happened: Retail traders have been net sellers of the majority of the ‘Magnificent Seven’ stocks, with a focus on pharmaceuticals like Eli Lilly And Co LLY, JPMorgan analysts noted in a report on Wednesday, as reported by Business Insider.

Over the past week, individual traders have sold off $1.4 billion worth of individual stocks, including major players like Tesla Inc TSLA, Apple Inc AAPL, Alphabet Inc GOOG GOOGL, and Microsoft Corp MSFT.

However, NVIDIA Corp NVDA remains a popular choice among retail traders, but there has been a noticeable shift towards big pharma players such as Eli Lilly, Pfizer Inc PFE, and Ozempic maker Novo Nordisk NVO.

See Also: This Long-Time Dogecoin Bull Made A Valentine’s Day Prediction About DOGE, SHIB Comebacks — Here’s How It

Despite the ongoing AI-driven frenzy, there are signs of it cooling off. Goldman Sachs reported in late February that hedge funds were selling tech stocks at the fastest pace in seven months, following a six-week buying streak leading up to Nvidia’s quarterly earnings.

Why It Matters: The shift in retail trader focus from tech to pharma stocks is indicative of a broader trend in the market. This development comes on the heels of concerns raised by Wall Street veteran Ed Yardeni about the vulnerability of some of the Magnificent Seven stocks, including Tesla and Apple.

Meanwhile, the era of the Magnificent Seven, a term popularized by analyst Mike O’Rourke, is reportedly coming to an end as the fortunes of these tech giants have diverged sharply in recent months.

Amidst these shifts, the AI-driven frenzy has also been a cause for concern, with Apollo Global Management chief economist Torsten Sløk warning that the current AI bubble is bigger than the 1990s tech bubble.

Read Next: Bitcoin, Ethereum, Dogecoin Tumble As $1.15B Worth Of Crypto Liquidations Loom: Analyst Predicts 55% Correction For King Crypto To $35K Levels

Image Via Shutterstock


Engineered by Benzinga Neuro, Edited by Kaustubh Bagalkote


The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.


Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: EquitiesNewsHealth CareMarketsJPMorganKaustubh BagalkoteMagnificent SevenPharma Stocksretail traders
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!